PERCENT
Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff
NGM, Genomics, Fierce, 8, Generalized, Staff, 75%, 2025
Trump signs sweeping executive order to cut US drug prices by ‘up to 90%’
Prices, HHS, United States, Transplant Registry Unified Management Program, Policy
Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff
Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular, gene therapy, 95%
Teva plots thousands of job cuts as restructuring drive enters ‘acceleration’ phase
Workforce reduction (8%), $700 million cost savings, Strategic overhaul, Generics to biopharmaceuticals pivot, Operational streamlining, R&D investment
Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides
MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1
CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%
Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes
Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC
Emi-Le, Mersana, VTCN1 gene, Antibody-Drug Conjugates, emiltatug ledadotin, Malignant neoplasm of breast, 55%
Exact Sciences plans ‘transformative year’ with 3 cancer test debuts
Science, MRD, Exact brand biomedical or dental material, Hypersensitivity
Immunic’s MS drug shows ‘modest’ brain volume impact, stock tumbles
Multiple Sclerosis, brain volume, Progressive, vidofludimus, calcium, Disability
Novartis to buy Regulus Therapeutics for up to $1.7B
Goldcrest, Novartis, Acquisition (action), Kidney Diseases